Toukeibu Gan
Online ISSN : 1881-8382
Print ISSN : 1349-5747
ISSN-L : 1349-5747
A case of HER2 positive primary unknown adenocarcinoma with cervical lymph node metastasis treated with Trastuzumab-based targeted therapy
Kazushi FujiyamaHirotsugu HashimotoSadahiro KishishitaKeita UchinoKazunari Nakao
Author information
JOURNAL FREE ACCESS

2025 Volume 51 Issue 1 Pages 37-40

Details
Abstract
HER2 overexpression is also seen in cases of adenocarcinoma, breast cancer, gastric cancer, etc. Amongst head and neck cancers, salivary duct carcinoma is the most well-known histological type. However, reports of HER2 positive primary unknown adenocarcinoma with cervical lymph node metastasis are extremely rare. We experienced a case of HER2 positive primary unknown adenocarcinoma with cervical lymph node metastasis. A 56-year-old male, who complained of a neck mass, had multiple lymph node enlargement, a tumor in the left lobe of the thyroid and multiple pulmonary nodules. Lymphadenectomy showed GCDFP-15 positive adenocarcinoma with apocrine differentiation. Primary tumor was not indicated by various examinations, and no result suggested a diagnosis of thyroid cancer or salivary duct cancer. While starting to treat the patient as primary unknown cancer, we performed comprehensive genome profiling. ERBB2 was highly amplified, and immunostaining showed HER2(3+). Following treatment as HER2 positive breast cancer, the patient has shown a partial response for 3 years until now.
Content from these authors
© 2025 Japan Society for Head and Neck Cancer
Previous article
feedback
Top